Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25323875 | 1.00 | NOS3 (0.37) | NOS3NOS1NOS2CYP11B2CYP11B1 | |
| SCHEMBL25323877 | 1.00 | NOS3 (0.37) | NOS3NOS1NOS2CYP11B2CYP11B1 | |
| SCHEMBL24367119 | 0.83 | NOS3 (0.41) | NOS3NOS1NOS2CHRNB4CHRNA3 | |
| SCHEMBL30551361 | 0.81 | IDH1 (0.38) | NOS3NOS1NOS2CHRNB2CHRNB4 | |
| SCHEMBL30470217 | 0.81 | IDH1 (0.38) | NOS3NOS1NOS2CHRNB2CHRNB4 | |
| SCHEMBL25322604 | 0.81 | IDH1 (0.38) | NOS3NOS1NOS2CHRNB2CHRNB4 | |
| SCHEMBL24233803 | 0.81 | IDH1 (0.38) | NOS3NOS1NOS2CHRNB2CHRNB4 | |
| SCHEMBL25322415 | 0.81 | IDH1 (0.41) | NOS3NOS1NOS2CYP11B2CYP11B1 | |
| SCHEMBL25322417 | 0.81 | IDH1 (0.41) | NOS3NOS1NOS2CYP11B2CYP11B1 | |
| SCHEMBL30550980 | 0.81 | IDH1 (0.41) | NOS3NOS1NOS2CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | NOS3 3132/4885NOS1 2495/4885NOS2 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.